LivaNova To Present Eight Posters At AES Highlighting VNS Therapy's Seizure Reduction And Improved Outcomes In Drug-Resistant Epilepsy

Eight scientific posters demonstrate significant seizure reduction and improved outcomes with VNS Therapy in patients with Drug-Resistant Epilepsy

LivaNova PLC (NASDAQ:LIVN), a market-leading medical technology company, today announced it will present eight posters at the American Epilepsy Society (AES) Annual Meeting, taking place Dec. 5-9 in Atlanta. These presentations highlight real-world evidence from the CORE-VNS study, the largest prospective, multinational observational study of VNS Therapy™ for Drug-Resistant Epilepsy (DRE), and new health economics analyses.